This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Emergent BioSolutions, Inc.
Drug Names(s): Recombinant Protective Antigen Anthrax Vaccine, Purified, rPA102
Description: The active ingredient of VaxGen's anthrax vaccine is a clone of Protective Antigen (rPA) that is designed to prompt the immune system to produce antibodies that neutralize anthrax toxins. It is a reformulated and potentially more stable form of the rPA 102 vaccine originally developed at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
Deal Structure: In November 2007, VaxGen and Raven announced that their respective boards of directors have unanimously approved a definitive merger agreement.
In March 2008, VaxGen and Raven terminated their merger agreement in light of stronger than anticipated opposition to the proposed merger by VaxGen stockholders.
In May 2008, VaxGen completed the sale of all assets and rights related to its rPA anthrax vaccine product candidate and related technology to Emergent BioSolutions. Under the terms of the transaction, Emergent BioSolutions paid VaxGen $2 million upon execution of the definitive agreement and may be obligated to pay up to an additional $8 million in milestone payments, plus specified percentages of future net sales.
In April 2010, VaxGen and diaDexus, a privately held diagnostics company, announced that they have entered into a non-binding Summary of Terms pursuant to which it is contemplated that, if a definitive agreement is entered into and requisite approvals are...See full deal structure in Biomedtracker
Partners: diaDexus, Inc.
Additional information available to subscribers only: